#France #Lyon #genOway #Antibody Therapy #Fcγ receptors

genOway's Revolutionary Mouse Model: Redefining Antibody Therapy Predictions

Antibody therapies have become a linchpin in the treatment arsenal for cancer, inflammatory diseases, and a range of infections. However, the path from lab to clinic often encounters serious hurdles, as many promising drug candidates fail during clinical trials. A pathbreaking study published in Science Immunology introduces a groundbreaking solution from genOway: the genO-hFcγR mouse model. This innovative model enables a more accurate prediction of therapeutic antibody efficacy and safety in human contexts, addressing critical shortcomings in conventional testing methods.

The Challenge of Species-Specificity

One of the significant setbacks in antibody therapy development has been the reliance on standard laboratory mice for preclinical testing. Fcγ receptors, which play a pivotal role in immune responses by binding therapeutic antibodies, are not uniform across species. The differences in these receptors mean that treatments that appear effective and safe in mice can yield entirely different outcomes in humans. Consequently, this discrepancy results in costly late-stage failures that not only delay access to potentially life-saving therapies but also waste vital resources in the biopharmaceutical industry.

Breaking New Ground with genO-hFcγR

The genO-hFcγR mouse model stands to change the narrative. By specifically humanizing the Fcγ receptors, this model allows for a more relevant and nuanced understanding of how therapeutic antibodies will behave in humans. Researchers can assess which antibody candidates are likely to be most effective, based on their ability to target human immune cells effectively. The model not only aids in ranking selected candidates for efficacy but also provides insights about their potential to mitigate disease progress. With this early-stage visibility, researchers can make more informed decisions, accelerating the overall drug development process.

Collaboration Across Borders

The development of such an advanced model required an exceptional level of collaboration and expertise. This project brought together an international consortium of leading biopharmaceutical companies, showcasing a robust pooling of knowledge across multiple fields, including mouse genetics, antibody biology, and human immunology. Key players in this consortium include:

• - genOway (France): A pioneer in developing predictive preclinical models.
• - argenx (Belgium): Innovators in Fc-engineering and FcRn biology.
• - Innate Pharma (France): Experts in natural killer cell-based immunotherapies.
• - Vir Biotechnology (USA): Focused on immunotherapy advancements.
• - VIB-Ghent University (Belgium): A premier immunology research institution that played a critical role in the modeling and publication of study results.

By leveraging their combined expertise, these collaborators have substantially enhanced our understanding of human disease through the refined lens of the genO-hFcγR mouse model.

A Resource for the Scientific Community

Since its launch to the scientific community in 2024, the genO-hFcγR model has rapidly gained traction among biopharmaceutical companies and nonprofit organizations alike. Notably, it has become instrumental in advancing the preclinical programs of notable entities such as the Gates Foundation, which relies on this model for critical global health research initiatives. For more detailed insights on this groundbreaking research, you can view the study here and the genO-hFcγR introduction video here.

In summary, genOway's genO-hFcγR mouse model not only enhances the predictive accuracy of antibody therapies but also plays a crucial role in bridging the gap between preclinical research and clinical success. As this innovative tool continues to gain acceptance in the scientific community, it is poised to usher in a new era of safer and more effective antibody therapies for patients around the world.